Market research
IMVT Immunovant Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 6B
- P/E ratio
- Not available
- Analyst target
- 48.875
- Dividend yield
- Not available
- Beta
- 0.84
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 6B
- P/E ratio
- Not available
- Analyst target
- 48.875
- Dividend yield
- Not available
- Beta
- 0.84
About
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Research context
Immunovant Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the IMVT discussion.
5 years, 7 months ago
Immunovant, Inc is currently in a long term downtrend where the price is trading 62.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Immunovant, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 181.3% to $-32M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.3% to $-23M since the same quarter in the previous year.
Based on the above factors, Immunovant, Inc gets an overall score of 2/5.